Home › Research › Treatments
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, Pourcher E, Gray J et al.. Movement disorders : official journal of the Movement Disorder Society, 2012-08-22
Topic: Risk, prevention and care in population studies
Parkinson's disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dubois, B., Tolosa, E., Katzenschlager, R., Emre, M., Lees, A. J., Schumann, G., et al. (2012). Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.25098
Vancouver
Dubois B, Tolosa E, Katzenschlager R, Emre M, Lees AJ, Schumann G, et al. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Movement disorders : official journal of the Movement Disorder Society. 2012. doi:10.1002/mds.25098. PMID: 22915447.
BibTeX
@article{dubois2012-22915447,
author = {Dubois, B. and Tolosa, E. and Katzenschlager, R. and Emre, M. and Lees, A. J. and Schumann, G. and Pourcher, E. and Gray, J. and others},
title = {{Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study}},
journal = {Movement disorders : official journal of the Movement Disorder Society},
year = {2012},
doi = {10.1002/mds.25098},
pmid = {22915447},
url = {https://doi.org/10.1002/mds.25098}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD.
- PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks.
- Coprimary end points were the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinician's Interview-Based Impression of Change plus caregiver input (CIBIC+; global function).
- Secondary end points measured executive function, attention, activities of daily living (ADLs), and behavioral symptoms.
Why it matters
This randomized, double-blind study gave donepezil at 5 or 10 mg or placebo to 550 patients with Parkinson's disease dementia for 24 weeks. It tests a treatment for Parkinson's disease dementia, not Alzheimer's disease, and the provided findings do not report whether donepezil worked.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants550
- Evidence strengthHigh
How this study scored 70/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society) |
| Journal's citation record | 3 / 4 | Movement Disorders: journal h-index 281 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 550 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 201 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 12.6 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 4 / 6 | Cited 9.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 2 / 4 | Cited 27 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Margaret L. Moline: h-index 41 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | Inserm: institution h-index 1,988 (OpenAlex) |
| Multi-centre collaboration | 3 / 3 | OpenAlex lists 15 institution(s) in 7 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22915447) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 70 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.